National Heart, Lung, and Blood Institute, BDR Contracts Section, Contracts Operations Branch, Federal Building, Room 610, National Institutes of Health, Bethesda, MD 20892

A -- HYDROXYUREA FOLLOW-UP STUDY SOL NHLBI-HB-95-04 DUE 040395 POC Joann A. Ciufolo, Contract Specialist, (301) 496-3513. The National Heart, Lung, and Blood Institute intends to negotiate a sole source procurement with Maryland Medical Research Institute, Baltimore, Maryland. The contractor will be responsible for clinical follow-up of the patients, submission of health status forms, and coordination with the clinical centers for the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Follow-up Study. The MSH study began in 1991, with Maryland Medical Research Institute providing data management and statistical support and coordination with the 21 clinical centers involved in the MSH study. The Hydroxyurea Follow-Up Study is a five-year longitudinal epidemiologic study of MSH patients to ascertain long-term toxic effects of hydroxyurea usage in the sickle cell anemia patient population who participated in MSH. The period of performance of the contract is expected to be January 1, 1996 through December 31, 2000. The authority to use other than full and open competition is 41 U.S.C. 253(c)(1) as set forth in FAR 6.302-1(b)(1). Maryland Medical Research Institute has the unique capability to provide the required services to the NHLBI without substantive duplication of cost and unacceptable delays. SEE Note 22. (0040)

Loren Data Corp. http://www.ld.com (SYN# 0003 19950210\A-0003.SOL)